Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Allogene Therapeutics (ALLO) Profit After Tax (2019 - 2025)

Allogene Therapeutics' Profit After Tax history spans 7 years, with the latest figure at -$41.4 million for Q3 2025.

  • For Q3 2025, Profit After Tax rose 37.55% year-over-year to -$41.4 million; the TTM value through Sep 2025 reached -$212.0 million, up 23.32%, while the annual FY2024 figure was -$257.6 million, 21.29% up from the prior year.
  • Profit After Tax for Q3 2025 was -$41.4 million at Allogene Therapeutics, up from -$50.9 million in the prior quarter.
  • Across five years, Profit After Tax topped out at -$33.0 million in Q1 2021 and bottomed at -$1.2 billion in Q4 2022.
  • The 5-year median for Profit After Tax is -$70.9 million (2021), against an average of -$173.1 million.
  • The largest annual shift saw Profit After Tax tumbled 141.86% in 2022 before it surged 93.62% in 2023.
  • A 5-year view of Profit After Tax shows it stood at -$903.3 million in 2021, then crashed by 36.83% to -$1.2 billion in 2022, then soared by 93.62% to -$78.8 million in 2023, then increased by 23.98% to -$59.9 million in 2024, then skyrocketed by 30.93% to -$41.4 million in 2025.
  • Per Business Quant, the three most recent readings for ALLO's Profit After Tax are -$41.4 million (Q3 2025), -$50.9 million (Q2 2025), and -$59.7 million (Q1 2025).